Mycobacterium tuberculosis cytochrome P450 enzymes: A cohort of novel TB drug targets

Sean A. Hudson, Kirsty J. McLean, Andrew W. Munro, Chris Abell

Research output: Contribution to journalConference article

20 Citations (Scopus)

Abstract

TB (tuberculosis) disease remains responsible for the death of over 1.5 million people each year. The alarming emergence of drug-resistant TB has sparked a critical need for new front-line TB drugs with a novel mode of action. In the present paper, we review recent genomic and biochemical evidence implicating Mycobacterium tuberculosis CYP (cytochrome P450) enzymes as exciting potential targets for new classes of anti-tuberculars. We also discuss HTS (high-throughput screening) and fragment-based drug-discovery campaigns that are being used to probe their potential druggability.

Original languageEnglish
Pages (from-to)573-579
Number of pages7
JournalBiochemical Society Transactions
Volume40
Issue number3
Early online date22 May 2012
DOIs
Publication statusPublished - 1 Jun 2012
Externally publishedYes
EventBiochemical Society Annual Symposium: Frontiers in Biological Catalysis - Robinson College, Cambridge, United Kingdom
Duration: 10 Jan 201212 Jan 2012
https://www.rsc.org/events/detail/6826/annual-symposium-frontiers-in-biological-catalysis

Fingerprint Dive into the research topics of 'Mycobacterium tuberculosis cytochrome P450 enzymes: A cohort of novel TB drug targets'. Together they form a unique fingerprint.

  • Cite this